肿瘤标志物CA724、CEA、CA242、CA199联合检测在胃癌临床诊断中的价值

The value of combined detection of tumor markers of CA724,CEA,CA242 and CA199 in clinical diagnosis of gastric cancer

目的分析胃癌患者采取肿瘤标志物糖类抗原724(CA724)、癌胚抗原(CEA)、糖类抗原242(CA242)、糖类抗原199(CA199)联合检测的诊断价值。方法选择68例胃癌确诊患者作为观察组,另选择68例良性胃疾病患者作为对照组,两组均接受肿瘤标志物(CA724、CEA、CA242、CA199)检测。比较两组患者肿瘤标志物指标(CA724、CEA、CA242、CA199),观察组不同分期患者肿瘤标志物指标及各项肿瘤标志物单一检测和联合检测的阳性率。结果观察组患者的CA724、CEA、CA242、CA199分别为(8.49±1.13)U/ml、(6.11±0.51)ng/ml、(25.89±3.02)U/ml、(41.14±5.02)U/ml,均明显高于对照组的(1.69±0.13)U/ml、(2.30±0.56)ng/ml、(3.97±0.11)U/ml、(10.40±3.22)U/ml,差异具有统计学意义(P<0.05)。观察组Ⅳ期患者的CA724、CEA、CA242、CA199分别为(15.59±1.13)U/ml、(10.14±0.32)ng/ml、(33.93±3.02)U/ml、(53.39±5.15)U/ml,均明显高于Ⅰ期的(6.38±1.04)U/ml、(4.96±0.33)ng/ml、(19.89±2.03)U/ml、(36.68±4.49)U/ml和Ⅱ期的(7.55±1.02)U/ml、(6.18±0.35)ng/ml、(23.48±3.05)U/ml、(40.94±3.27)U/ml及Ⅲ期的(8.94±1.06)U/ml、(7.79±0.31)ng/ml、(28.18±3.13)U/ml、(48.11±5.26)U/ml,差异均有统计学意义(P<0.05)。CA724、CEA、CA242、CA199单一检测和联合检测的阳性率分别为82.35%、70.59%、67.65%、66.18%、100.00%,CA724、CEA、CA242、CA199联合检测的阳性率高于各项单一检测,差异具有统计学意义(P<0.05)。结论临床可通过肿瘤标志物联合检测方法鉴别诊断胃癌,同时根据测定结果判断患者癌症分期情况,准确性高,操作简单,提倡推广采用。

Objective To analyze the the value of combined detection of tumor markers of carbohydrate antigen 724(CA724),carcinoembryonic antigen(CEA),carbohydrate antigen 242(CA242),carbohydrate antigen 199(CA199)in the diagnosis of gastric cancer.Methods 68 patients with diagnosed gastric cancer were selected as the observation group,and 68 patients with benign gastric diseases were selected as the control group.Both groups received tumor markers(CA724,CEA,CA242,CA199)detection.Comparison was made on tumor markers(CA724,CEA,CA242,CA199)between the two groups,the tumor markers in patients with different stages in the observation group,as well as the positive rates of single detection and combined detection of each tumor marker.Results The CA724,CEA,CA242,and CA199 in the observation group were(8.49±1.13)U/ml,(6.11±0.51)ng/ml,(25.89±3.02)U/ml,and(41.14±5.02)U/ml,which were significantly higher than(1.69±0.13)U/ml,(2.30±0.56)ng/ml,(3.97±0.11)U/ml,and(10.40±3.22)U/ml in the control group,and the differences were all statistically significant(P<0.05).In the observation group,the CA724,CEA,CA242 and CA199 of stageⅣpatients were(15.59±1.13)U/ml,(10.14±0.32)ng/ml,(33.93±3.02)U/ml,and(53.39±5.15)U/ml,which were obviously higher than those of stageⅠpatients[(6.38±1.04)U/ml,(4.96±0.33)ng/ml,(19.89±2.03)U/ml,and(36.68±4.49)U/ml],stageⅡpatients[(7.55±1.02)U/ml,(6.18±0.35)ng/ml,(23.48±3.05)U/ml,(40.94±3.27)U/ml]and stageⅢpatients[(8.94±1.06)U/ml,(7.79±0.31)ng/ml,(28.18±3.13)U/ml,(48.11±5.26)U/ml],and the differences were all statistically significant(P<0.05).The positive rates of single and combined detection of CA724,CEA,CA242 and CA199 were 82.35%,70.59%,67.65%,66.18%and 100.00%,respectively;the positive rate of combined detection of CA724,CEA,CA242 and CA199 was higher than that of single index detection,and the difference was statistically significant(P<0.05).Conclusion Clinically,the combined detection of tumor markers can be used to differentially diagnose gastric cancer disease,and at the same time,the patient's cancer stage can be judged according to the measurement results,with high accuracy and simple operation.It is suggested to be promoted and applied.